Osteosarcoma
MONDO:0009807A usually aggressive malignant bone-forming mesenchymal neoplasm, predominantly affecting adolescents and young adults. It usually involves bones and less frequently extraosseous sites. It often involves the long bones (particularly distal femur, proximal tibia, and proximal humerus). Pain with or without a palpable mass is the most frequent clinical symptom. It may spread to other anatomic sites, particularly the lungs.
Also known as: bone tissue neoplasm, osteogenic sarcoma, osteoid sarcoma, osteosarcoma, osteosarcoma (disease), osteosarcoma, malignant, sarcoma of osteoid
2925 clinical trials for this condition and its sub-types, 169 tagged with Osteosarcoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Osteosarcoma
-
Localized osteosarcoma 13 trials
-
Bone osteosarcoma 8 trials
5 sub-types
- Conventional osteosarcoma 0 trials Sub-types →
- Metachronous osteosarcoma of the bone 0 trials
- Osteosarcoma arising in bone Paget disease 0 trials
- Peripheral osteosarcoma 0 trials Sub-types →
- Telangiectatic osteogenic sarcoma 0 trials
-
Pediatric osteosarcoma 8 trials
3 sub-types
- Childhood extraosseous osteosarcoma 0 trials
- Childhood intracortical osteosarcoma 0 trials
- Childhood parosteal osteosarcoma 0 trials
-
Extraosseous osteosarcoma 2 trials
7 sub-types
- Adult extraskeletal osteosarcoma 0 trials
- Breast extraskeletal osteosarcoma 0 trials
- Central nervous system extraskeletal osteosarcoma 0 trials
- Childhood extraosseous osteosarcoma 0 trials
- Kidney osteogenic sarcoma 0 trials
- Liver extraskeletal osteosarcoma 0 trials
- Mediastinal extraskeletal osteosarcoma 0 trials
-
Low grade central osteosarcoma 0 trials
-
Multifocal osteogenic sarcoma 0 trials
2 sub-types
Most studied deeper sub-types
-
New antibody cocktail takes aim at tough childhood cancers
Disease control Stopped earlyThis early-phase trial tested two lab-made antibodies, magrolimab and dinutuximab, together in 12 children and young adults whose neuroblastoma or osteosarcoma had returned or stopped responding to treatment. The main goal was to find a safe dose and watch for side effects. Resea…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Cancer drug cabozantinib tested in kids and young adults with bone cancer
Disease control Stopped earlyThis study tested the drug cabozantinib in children, teens, and young adults with osteosarcoma (a bone cancer) that could not be fully removed by surgery. Participants who had stable or partially improved disease after chemotherapy received either cabozantinib plus best supportiv…
Phase 2 • Sponsor: Ipsen • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Cancer drug combo trial for kids halted early
Disease control Stopped earlyThis early-stage study tested a combination of two drugs, niraparib and dostarlimab, in children and teens (ages 6 months to 17 years) with solid tumors that had come back or were not responding to treatment. The goal was to find a safe dose and see if the drugs could shrink tumo…
Phase 1 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Experimental combo targets Hard-to-Treat bone cancer
Disease control Stopped earlyThis early-phase trial tested a combination of two drugs—TQB2928 (an antibody that helps the immune system attack cancer cells) and anlotinib (a drug that cuts off tumor blood supply)—in 20 people with advanced osteosarcoma or other solid tumors that had stopped responding to sta…
Phase 1 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC